Nothing said here yet.
to join the conversation.
| French Glendon E. IIIPresident and CEO | Sell | 37,784 | $85.4K | Tue, Sep 1 |
| Radhakrishnan SrikanthChief Science & Techn. Officer | Sell | 5,863 | $13.3K | Tue, Sep 1 |
| Lehman David AaronGeneral Counsel | Sell | 4,827 | $10.9K | Tue, Sep 1 |
| French Glendon E. IIIPresident and CEO | Sell | 4,098 | $9.3K | Tue, Sep 1 |
| Lehman David AaronGeneral Counsel | Sell | 3,807 | $8.6K | Tue, Sep 1 |
| Radhakrishnan SrikanthChief Science & Techn. Officer | Sell | 3,618 | $8.2K | Tue, Sep 1 |
| Lehman David AaronGeneral Counsel | Sell | 3,476 | $7.9K | Tue, Sep 1 |
| Radhakrishnan SrikanthChief Science & Techn. Officer | Sell | 2,643 | $6.0K | Tue, Sep 1 |
| Rose Geoffrey BeranChief Commercial Officer | Sell | 2,390 | $5.4K | Tue, Sep 1 |
| Lehman David AaronGeneral Counsel | Sell | 2,224 | $5.0K | Tue, Sep 1 |
| Rose Geoffrey BeranChief Commercial Officer | Sell | 2,213 | $5.0K | Tue, Sep 1 |
| Radhakrishnan SrikanthChief Science & Techn. Officer | Sell | 2,121 | $4.8K | Tue, Sep 1 |
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Revenue returned to growth while losses narrowed significantly on cost discipline.
Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market.
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif., Oct.
Tes Pharma Will Use the elive™ Platform to Functionally Evaluate Response to TES-4207 in Live Tumor Fragments as a Monotherapy and in Combination With Immune Checkpoint Inhibitors MADISON, Wis., Sept.
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints THOUSAND OAKS, Calif., Sept.
Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2.